REG - AstraZeneca PLC - Directorate change

AstraZenecaAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260224:nRSX0809Ua&default-theme=true

RNS Number : 0809U  AstraZeneca PLC  24 February 2026

24 February 2026

 

 

Non-Executive Board Changes

 

AstraZeneca PLC announced today that Non-Executive Director Nazneen Rahman
will retire from the Board having joined in 2017. This will take effect at the
conclusion of the Company's AGM on 9 April 2026.

 

The Company also announced today that at the conclusion of the Company's AGM
on 9 April 2026:

·    Tony Mok will succeed Nazneen Rahman as Chair of the Sustainability
Committee and become a member of the Nomination and Governance Committee; and

·    Birgit Conix will become a member of the Sustainability Committee.

Michel Demaré, Chair of AstraZeneca, said "On behalf of the whole Board, I
would like to thank Nazneen Rahman for the significant contributions she has
made to our work as a Board, as well as the insights, experience and
leadership she brought to our Board Committees. Nazneen has been with us since
2017 and we have benefited from her specialist experience in genetics research
and translation, sustainable healthcare as well as her passion for open
science and science communication. Nazneen has been a member of the Science
Committee throughout her tenure, chairing it from 2017 to 2023, and has been
Chair of the Sustainability Committee since its establishment in 2021. She has
also served on the Remuneration Committee and Nomination and Governance
Committees."

 

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Social Media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) .

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

 

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASEDFUDEMSEDE



            Copyright 2019 Regulatory News Service, all rights reserved